EGFR and esophageal squamous cell carcinoma: As a downstream target of miR-224, differentially expressed in squamous cell carcinoma 1 (DESC1) is downregulated in ESCC; it attenuates the chemoresistance of ESCC cells to 5-FU or cisplatin by downregulating the EGFR/AKT pathway [128].